All Releases
 |
Momenta Pharmaceuticals Announces Results From a Phase 1 Study of M118 Administered as a Subcutaneous Injection
Jul 29, 2008
|
18.2 KB |
|
| |
CAMBRIDGE, Mass., Jul 29, 2008 (PrimeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today will present safety and tolerability results from a Phase I study of M118, its rationally engineered anticoagulant, in a poster pr...
|
|
Momenta Pharmaceuticals Announces Results from M118 Drug-Drug Interaction Study with Aspirin and Clopidogrel
Jul 28, 2008
|
17.5 KB |
|
| |
CAMBRIDGE, Mass., Jul 28, 2008 (PrimeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today presented results from a Phase 1 study of M118, its rationally engineered anticoagulant, demonstrating the absence of a significan...
|
|
Momenta Pharmaceuticals Announces Data Presentations On M118 At Upcoming IXth World Conference On Clinical Pharmacology and Therapeutics Meeting
Jul 25, 2008
|
14.3 KB |
|
| |
CAMBRIDGE, Mass., Jul 25, 2008 (PrimeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that clinical data for its rationally engineered anticoagulant, M118, will be presented at the upcoming IXth World Confe...
|
|
Momenta Pharmaceuticals Reports Financial Results for the Second Quarter of 2008
Jul 24, 2008
|
19.8 KB |
|
| |
CAMBRIDGE, Mass., Jul 24, 2008 (PrimeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced its financial results for the second quarter and six months ended June 30, 2008.
For the second quarter of 2008, the...
|
|
Momenta Pharmaceuticals Appoints Bruce A. Leicher as General Counsel
Jul 24, 2008
|
14.5 KB |
|
| |
CAMBRIDGE, Mass., Jul 24, 2008 (PrimeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Bruce A. Leicher, J.D. has been appointed as the Company's Senior Vice President and General Counsel.
Craig A. ...
|
|
Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for Second Quarter 2008 Financial Results
Jul 18, 2008
|
14.6 KB |
|
| |
CAMBRIDGE, Mass., Jul 18, 2008 (PrimeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will report its financial results for the second quarter ended June 30, 2008 before the U.S. financial markets open on Thursday, July 24...
|
|
Momenta Pharmaceuticals Announces Filing of Abbreviated New Drug Application With a Paragraph IV Certification for Generic Version of Copaxone
Jul 11, 2008
|
17.1 KB |
|
| |
CAMBRIDGE, Mass., Jul 11, 2008 (PrimeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for...
|
|
Momenta Pharmaceuticals Announces Appointment of James R. Sulat to Board of Directors
Jun 11, 2008
|
14.6 KB |
|
| |
CAMBRIDGE, Mass., Jun 11, 2008 (PrimeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of James R. Sulat, Chief Financial Officer and Director of Memory Pharmaceuticals Corp., to its Board of...
|
|
Momenta Pharmaceuticals to Present At the Seventh Annual Needham Biotechnology & Medical Technology Conference
May 29, 2008
|
14.2 KB |
|
| |
CAMBRIDGE, Mass., May 29, 2008 (PrimeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Richard Shea, Chief Financial Officer, will deliver a corporate presentation at the Seventh Annual Needham Biotechn...
|
|
Momenta Pharmaceuticals to Present At 2008 Citi Investment Research Global Healthcare Conference
May 15, 2008
|
14.2 KB |
|
| |
CAMBRIDGE, Mass., May 15, 2008 (PrimeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Richard Shea, Chief Financial Officer, will deliver a corporate presentation at the 2008 Citi Investment Research G...
|
|
Momenta Pharmaceuticals Announces Date for 2008 Annual Meeting of Stockholders
May 15, 2008
|
13.9 KB |
|
| |
CAMBRIDGE, Mass., May 15, 2008 (PrimeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will hold its Annual Meeting of Stockholders on June 4, 2008 at 10:00 am EDT at the offices of Wilmer Cutler Pic...
|
|
Momenta Pharmaceuticals Reports Financial Results for the First Quarter of 2008
May 7, 2008
|
20.8 KB |
|
| |
CAMBRIDGE, Mass., May 7, 2008 (PrimeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the quarter ended March 31, 2008.
For the first quarter of 2008, the Company reported a net ...
|
|
Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for First Quarter 2008 Financial Results
May 1, 2008
|
14.6 KB |
|
| |
CAMBRIDGE, Mass., May 1, 2008 (PrimeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will report its financial results for the first quarter ended March 31, 2008 before the U.S. financial markets open on Wednesday, May 7, ...
|
|
Momenta Pharmaceuticals Receives Regulatory Guidance On M-Enoxaparin ANDA
Apr 29, 2008
|
16.3 KB |
|
| |
CAMBRIDGE, Mass., Apr 29, 2008 (PrimeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the Food and Drug Administration (FDA) has provided guidance regarding the Abbreviated New Drug Application (ANDA) ...
|
|
Momenta Pharmaceuticals to Present At Deutsche Bank 33rd Annual Health Care Conference
Apr 28, 2008
|
14.2 KB |
|
| |
CAMBRIDGE, Mass., Apr 28, 2008 (PrimeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Craig Wheeler, Chief Executive Officer, will deliver a corporate presentation at the Deutsche Bank 33rd Annual Heal...
|
|
Momenta Pharmaceuticals to Present At 2008 Morgan Stanley Global Healthcare Unplugged Conference
Apr 23, 2008
|
14.3 KB |
|
| |
CAMBRIDGE, Mass., Apr 23, 2008 (PrimeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Craig Wheeler, Chief Executive Officer, will deliver a corporate presentation at the 2008 Morgan Stanley Global Hea...
|
|
Momenta Pharmaceuticals Announces Presentation of M118 Phase 1 Results At the American Society for Clinical Pharmacology and Therapeutics Annual Meeting
Apr 4, 2008
|
18.9 KB |
|
| |
CAMBRIDGE, Mass., Apr 4, 2008 (PrimeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, announced today that clinical data from a Phase 1 study of M118, the Company's rationally engineered anticoagulant, will be presented at ...
|
|
Momenta Pharmaceuticals to Present At Cowen and Company 28th Annual Health Care Conference
Mar 11, 2008
|
14.2 KB |
|
| |
CAMBRIDGE, Mass., Mar 11, 2008 (PrimeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Ian Fier, Vice President, Development Operations, will deliver a corporate presentation at the Cowen and Company 28...
|
|
Momenta Pharmaceuticals Appoints Dr. James M. Roach as Chief Medical Officer
Mar 4, 2008
|
14.9 KB |
|
| |
CAMBRIDGE, Mass., Mar 4, 2008 (PrimeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that James M. Roach, M.D., has been appointed as the Company's new Chief Medical Officer and Senior Vice President of Dev...
|
|
Momenta Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year End 2007
Feb 14, 2008
|
22.4 KB |
|
| |
CAMBRIDGE, Mass., Feb 14, 2008 (PrimeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the fourth quarter and year ended December 31, 2007.
For the fourth quarter of 2007, the Co...
|
|
|
